Artificial intelligence is revolutionising the pharmaceutical and biotechnology industries. Its unparalleled power to make predictions based on large data sets is advancing understanding of diseases, improving diagnostic speed and accuracy, accelerating drug discovery, and improving clinical trials.
AI’s rapid growth makes it more important than ever for companies to safeguard their intellectual property.
AI and drug discovery
AI has tremendous power to identify, and even design, new therapeutic candidates using existing data. For example, AI can predict structure-function relationships for small-molecule drugs, identify new targets, and screen candidates by conducting molecular dynamics. Similarly, it can predict protein structure and function to identify new therapeutic candidates. These are just a few of the ways AI is improving drug discovery.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
